Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide (L47) for Injection in Chronic Hepatitis D – Phase III
ChiCTR2500115066Phase 3Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Viral Hepatitis B With Delta-Agent comparing L47 2.1 mg + entecavir with Placebo + entecavir (2 arms). Primary endpoints: HDV RNA and Alanine aminotransferase normalization. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
hepalatide
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on ChiCTR2500115066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115066.